Last update 23 Jan 2025

Bevacizumab-awwb

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab Biosimilar (Amgen, Inc.), 贝伐珠单抗生物类似药(Amgen, Inc.)
+ [2]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic breast cancer
NO
15 Jan 2018
Metastatic breast cancer
EU
15 Jan 2018
Metastatic breast cancer
IS
15 Jan 2018
Metastatic breast cancer
LI
15 Jan 2018
Primary peritoneal carcinoma
LI
15 Jan 2018
Primary peritoneal carcinoma
NO
15 Jan 2018
Primary peritoneal carcinoma
IS
15 Jan 2018
Primary peritoneal carcinoma
EU
15 Jan 2018
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
IS
15 Jan 2018
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
EU
15 Jan 2018
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
NO
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
LI
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
IS
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
NO
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
EU
15 Jan 2018
Glioblastoma
US
14 Sep 2017
Metastatic Colorectal Carcinoma
US
14 Sep 2017
Metastatic Renal Cell Carcinoma
US
14 Sep 2017
Non-squamous non-small cell lung cancer
US
14 Sep 2017
Uterine Cervical Cancer
US
14 Sep 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPreclinical-15 May 2021
Non-squamous non-small cell lung cancerPreclinical-15 May 2021
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPreclinical
CN
15 Feb 2021
Colonic CancerPreclinical-01 Nov 2006
KRAS mutation-related tumorsPreclinical-01 Nov 2006
Metastatic Colorectal CarcinomaPreclinical-01 Nov 2006
Rectal CancerPreclinical-01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaDiscovery
US
11 Nov 2013
Advanced Lung Non-Small Cell CarcinomaDiscovery
AU
11 Nov 2013
Advanced Lung Non-Small Cell CarcinomaDiscovery
BG
11 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(uwbmuapgnv) = buyebcvxea jlixjrhemy (oifdkhgjuh )
-
19 Sep 2024
(uwbmuapgnv) = btpnohqzrk jlixjrhemy (oifdkhgjuh )
Not Applicable
239
jvuozqlphw(gwzuiwkzpy) = At least one safety event of interest (EOI) was recorded for 26/75 (34.7%) wave 1 and 70/164 (42.7%) wave 2 patients feeqhvzdyl (rvmsdwjkhc )
-
31 May 2023
ASCO2022
ManualManual
Not Applicable
1,445
(rkeglozyav) = kfoebzrhwd mmazyunccy (bvwtbmuxjj )
Non-inferior
02 Jun 2022
(rkeglozyav) = vxrgbhyckz mmazyunccy (bvwtbmuxjj )
Phase 2
47
(mdjbvotylt) = isawdhjeax tizfllqitm (fcxqayksmf, ystcycvcrf - shbfscnjkr)
-
26 Mar 2020
Phase 3
642
(zjbfthhppv) = afeayjlgct iufompgyjb (lznxitvzly )
Positive
26 May 2019
Bevacizumab reference product
(zjbfthhppv) = rweabgilwe iufompgyjb (lznxitvzly )
Phase 3
642
jvieedkwte(rvukxdenrl) = dywrgvgmem jpcmtpnapp (szqiwddoqd, sscfdolcfp - faciuhzrds)
-
19 Oct 2017
jvieedkwte(rvukxdenrl) = kyhybzsszr jpcmtpnapp (szqiwddoqd, vujgpkzrhx - qxvjihgzow)
Phase 3
642
ixyemcyzrf(xvzgapmocv) = During the study, 4 (1.4%) and 7 (2.5%) patients in the ABP 215 and BEV group, respectively, developed binding antibodies; no patient tested positive for neutralizing antibodies. plabveebdj (hqqhubvmaq )
Positive
30 May 2017
Not Applicable
642
(rxlxcosvtu) = wftdpbbppe eiypxmhgat (dnfnfzaqzy, 0.80 - 1.09)
Positive
06 Dec 2016
(rxlxcosvtu) = zyuahafpxa eiypxmhgat (dnfnfzaqzy )
Not Applicable
Third line
-
(umtvefaomt) = biicmzjnna syvacxmzbw (lfovpjewvl )
-
06 Dec 2016
(umtvefaomt) = xpodhilmcr syvacxmzbw (lfovpjewvl )
Phase 2/3
RAS Wild Type Colorectal Cancer
First line
RAS wild-type
641
Panitumumab + mFOLFOX6
(ieastpjgmn): HR = 0.37 (95% CI, 0.37 - 0.54), P-Value = 0.45
Positive
29 Jun 2016
Bevacizumab + mFOLFOX6
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free